Mar 15, 2023 / 02:15PM GMT
Huidong Wang - Barclays Bank PLC, Research Division - Research Analyst
Good morning, everyone. My name is Gena Wang. I'm senior biotech analyst at the Barclays. Welcome to Barclays Global Healthcare Conference. It is my great pleasure to introduce our next presenting company, Vir Biotechnology. With us today, we have Phillip Pang, Chief Medical Officer. We also have Howard Horn, our Chief Financial Officer. So maybe I will hand over to Phillip Pang to give a brief overview before I jump into Q&A.
Phillip Pang - Vir Biotechnology, Inc. - Executive VP, Chief Medical Officer & Interim Head of Research
Thank you, Gena. So as you know, Gena, we've been talking a lot over the last 6 years. So 2023 really poses to be a banner year for Vir. It's a very exciting year. We have 4 clinical programs reading out this year alone in HIV, hepatitis B, hepatitis delta and flu. And each one of these programs can drive transformative potential for patients and value to patients as well as to the company. Behind this clinical pipeline sits a robust research clinical, research
Vir Biotechnology Inc at Barclays Global Healthcare Conference Transcript
Feb 09, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers